The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma
Küçük Resim Yok
Tarih
2024
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Lippincott Williams and Wilkins
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies. © 2024 Lippincott Williams and Wilkins. All rights reserved.
Açıklama
Anahtar Kelimeler
Acral Malignant Melanoma; Adjuvant Therapy; Nivolumab, B Raf Kinase; Carboplatin; Dabrafenib; Interferon; Ipilimumab; Lactate Dehydrogenase; Mitogen Activated Protein Kinase; Nivolumab; Paclitaxel; Pembrolizumab; Programmed Death 1 Receptor; Temozolomide; Trametinib; Immune Checkpoint Inhibitor; Mas Receptor; Mas1 Protein, Human; Pdcd1 Protein, Human; Programmed Death 1 Receptor; Acral Melanoma; Adult; Aged; Article; Cancer Adjuvant Therapy; Cancer Staging; Cancer Survival; Clinical Assessment; Comparative Study; Controlled Study; Disease Free Survival; Distant Metastasis; Drug Efficacy; Female; Follow Up; Human; Lymph Node Metastasis; Major Clinical Study; Male; Melanoma; Middle Aged; Multicenter Study (Topic); Multiple Cycle Treatment; Multivariate Analysis; Observational Study; Overall Survival; Personal Experience; Retrospective Study; Statistically Significant Result; Treatment Duration; Treatment Indication; Tumor Localization; Very Elderly; Adjuvant Chemotherapy; Clinical Trial; Melanoma; Mortality; Multicenter Study; Pathology; Procedures; Skin Tumor; Treatment Outcome; Adult; Aged; Aged, 80 And Over; Chemotherapy, Adjuvant; Female; Humans; Immune Checkpoint Inhibitors; Male; Melanoma; Middle Aged; Neoplasm Staging; Programmed Cell Death 1 Receptor; Proto-Oncogene Mas; Retrospective Studies; Skin Neoplasms; Treatment Outcome
Kaynak
Journal of Immunotherapy
WoS Q Değeri
Scopus Q Değeri
Q1
Cilt
47
Sayı
5
